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Innovations
Infinity Pharmaceuticals
Back to the Future
from a medicinal chemistry stand- mics with a technology—small mol-
ecules—that is absolutely proven.”point yet yield the potency and se-
Also in the Harvard laboratory withlectivity found in natural products.
Infinity Pharmaceuticals, of Cam-
bridge, Massachusetts, believes
there is a better way to begin drug
discovery through a chemical biol- Foley was Jeffrey Tong, PhD, nowHarvard Roots
ogy approach enabled by novel Senior Director, Corporate StrategyFoley’s familiarity with the chemis-
chemistry. Infinity’s compound col- and Development at Infinity. Whiletry-driven approach at Infinity stems
lections mimic the diversity and pha- Foley developed technologies tofrom his graduate laboratory experi-
rmacophoric display of natural prod- create the molecules, Tong hadence in the laboratory of Stuart
ucts, but without the traditional worked on developing technologiesSchreiber at the Harvard Institute of
barriers associated with working for microarray printing that wereChemistry and Cell Biology (ICCB).
with natural products—difficulties later adapted by ICCB and InfinitySchreiber is also an Infinity cofoun-
with purification, identification of ac- to become a small molecule arrayder. Schreiber’s vision was to create
tive species, synthesis, analog de- screening platform. “There are ma-structurally diverse molecules that
velopment, and scale-up. “We’re jor classes of protein targets thattraditional combinatorial chemistry
about bringing the full power of were inaccessible to current com-couldn’t access. To do so required
modern synthetic organic chemistry pound collections,” explains Tong ofembracing tougher chemistry, ex-
to bear on the discovery of new the need for new drug discoveryplains Adelene Perkins, Infinity’s
chemical entities,” says Michael Fo- tools. “Historical chemical file col-
ley, PhD, cofounder and Vice Presi- lections were largely created to fo-
dent of Chemical Technologies at In- cus on the drug targets of interest
“Our chemical biologyfinity. over the last 20–30 years, things like
GPCRs, ion channels, kinases, andBack to the Future approach allows us to
According to Foley, the company’s proteases.” The result has been acapitalize on all the work
motto in bumper sticker language large collection of compounds built
done on genomics with awould be “back to the future.” “The up around those targets. “Everyone
has been mining in the same space,idea is that we are creating mole- technology—small mole-
cules as starting points for drug dis- so we are interested in looking atcules—that is absolutely
covery with the positive attributes other validated targets with prom-
proven.”found in natural products yet easily ise,” says Perkins.
Homing in on Non-Druggableconstructed reproducibly on a large –Adelene Perkins, Chief
scale,” he says. These molecules are TargetsBusiness Officer, Infinity
known in Infinity parlance as the In- According to Tong, many highly at-
Pharmaceuticalsfiniplex library, which the company tractive targets remain off limits to
hopes will represent functionally di- drug discovery because of their in-
verse and stereochemically rich in- tractability to current chemistries in
Chief Business Officer. “Dr.dustrially scalable molecules. “In identifying molecules with the right
Schreiber, through the ICCB, hasshort,” says Foley, “we are working potency, selectivity, and pharmaco-
perfected the technology over theon the types of molecules that are kinetic properties. The fundamental
past five years to take tough chemi-the greatest challenge for modern synthesis-driven approach at Infinity
cal transformations and make themsynthetic chemistry.” is leading the company to close in
robust enough to be used in high-Nature may have offered up sev- on that gap between interesting mol-
throughput synthesis,” she says. In-eral important natural products like ecules with potential clinical rele-
finity’s plan is to use its novel chem-Taxol and rapamycin, but the inher- vance and drug candidates. Says
istry to discover drugs, building offent difficulties in analoging and syn- Perkins, “We want to create whole
of the revolutions in biology and in-thesis often make natural products libraries of molecules against every
formation technology that they be-intractable starting points for drug protein in the body and have a recipe
lieve will be perfected by a revolutiondevelopment. According to Foley, for how to make them again in a
in chemistry. Says Perkins, “TheInfinity’s aim is to make med-chem- large-scale setting.” Examples of
value of the IT and biology revolu-friendly molecules that rival the potentially interesting targets in-
tions of the 1990s has not been fullycomplexity of natural product drugs. clude new and well-credentialed tar-
realized in drug discovery because“We can modify the building blocks gets arising from the human genome
it was not matched by a parallel rev-around them very simply and also sequencing projects. “There are
olution in chemistry. Our chemicalinvert the stereocenters at our many attractive targets for which
biology approach allows us to capi-choosing,” he explains. The hope is people have failed to raise relevant
chemical matter,” explains Foley.that the molecules will be tractable talize on all the work done on geno-
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Targets cited include PTB1B for type rectly modulating its function,” he tors member and part-time em-
ployee, “we have an incredible focusII diabetes, hepatitis C protease, says.
The real benefit with this technol-beta-secretase for Alzheimer’s dis- on informatics and information tech-
nology to make sure we are able andease, and numerous protein-protein ogy will be for proteins that are hard
to purify or in limited abundance.interactions. “Everyone in the indus- ready to capture meaning from all
the data we are generating,” saystry would say if you had a ligand “This is an extraordinarily efficient
way to parse through a very largeagainst those proteins or if you could Foley. “We are employing some very
leading edge computational effortsinterrupt that protein-protein inter- compound collection and get that
down to a smaller number of inter-action you would have something that we think are poised to be indus-
try leading.”very special,” he says. “There are esting compounds and then pro-
ceed to smaller-scale functionalprobably 40 to 50 important proteins Infinity’s vision includes mapping
small molecules against all the pro-lacking a drug against them.” assays,” says Foley. “That is to say,
we can do high-throughput screen-Three-Platform Screening teins in the human body. “Obviously,
the amount of information that needsProcess ing where others could not on cer-
tain targets.”Once synthesized, the molecules to be managed in mapping near-infi-
nite chemical space against all pro-are screened with one of three The third approach is to use chemi-
cal genetics in the form of phenotypicscreening platforms to find matches teins is orders of magnitude beyond
what people are used to dealing with,”with proteins of interest. The first is cell-based assays as a discovery
platform to allow the molecules toa traditional series of target-based says Perkins of the company’s heavy
investment in knowledge manage-biochemical assays. “There is noth- interact with every protein in a dis-
ease-relevant setting. “We are usinging proprietary about these types of ment systems. Moss brings informa-
tion industry experts to the com-assays,” explains Foley. “It is the tar- cell-based assays as a way to get
our molecules in front of every pro-gets that are unique because they pany, “not pharma/biotech people
turned informatician,” says Perkins,have been previously unavailable for tein within the cell and let nature tell
us what is important,” says Foley.traditional drug discovery methods.” but software professionals trained in
industries where lots of informationThe second approach, classified He comments that the company’s
most significant milestone is a largeby Infinity as its chemical genomics needs to be used quickly and agilely.
“He has created an environmentmethod, is the small molecule mi- collection of synthesized molecules
that are able to perturb biologicalcroarray. “In this approach, we use where we have an internal company
of software engineers and informati-small molecule microarrays to systems in a selective way in a num-
ber of high-throughput phenotypicscreen our molecules against hun- cians who are all about serving our
chemists and biologists with thedreds of proteins, including both cell-based assays. But Foley cites
the difficulty in performing thesetractable and previously intractable products they need.”
In its three key technology plat-targets, in a very efficient manner assays on a large scale to make them
useful for high-throughput screen-that nobody, or very few, could rival forms, chemistry, biology, and in-
formatics, a fundamental focus andin the industry,” explains Foley. In- ing. The key scientific endeavor with
this technology is to make sure thefinity hopes to exploit the power of strength at Infinity has been its abil-
ity to translate the work of the aca-small molecule microarrays as a detectable event observed in the
population of cells is relevant to dis-highly efficient method for discovery demic into utility in the industrial
pharmaceutical world. The missionof protein-ligand interactions and, ease initiation or progression. And,
it must also be linked to downstreamhopefully, the development of func- is single-minded: to find and de-
velop drugs that have eluded others.tionally relevant drug candidates. assays like animal models or biologi-
cal markers of that molecule’s effectAt the moment, Infinity scientists
Chemistry & Biology invites yourcan spot over 3000 small molecule in a human being for ultimate clinical
comments on this topic. Pleasecompounds onto one glass micro- proof of concept.
write to the editors at chembiol@scope slide in a manner similar to The company has not yet pro-
cell.com.DNA microarray technology. Minis- gressed to animal or human studies.
“We’ve got to parse through a largecule amounts of labeled protein, ei- Alice A. McCarthy is a freelance science
ther purified or from more complex number of data points first,” says writer based in Gloucester, MA (alice@
mixtures, are passed over these Foley. The company hopes to have alicemccarthy.com).
glass slides. “Anything that sticks is some molecules in animal models
perhaps as early as this year, witha found protein-ligand interaction,”
says Foley. In March 2003, scientists the medium-term goal of having de-
velopmental candidates for humangenerated over 1,000,000 data
points with 50,000 small molecule testing over the next five years.
Equal Emphasis on Informaticscompounds and 20 proteins. But Fo-
ley cautions that these initial assays Along with its chemistry and biology
programs, Infinity is also heavily in-do not provide a functional sense of
what is going on. “All you know is vested in its knowledge manage-
ment competencies. Thanks to thethat that protein and small molecule
have an affinity for each other, but input of cofounder Frank Moss, for-
merly of Tivoli and Bowstreet famethe binding of the small molecule to
a protein is a precondition for di- and now an Infinity Board of Direc-
